Edition:
United States

Lonza Group AG (LONN.S)

LONN.S on Virt-X Level 1

273.10CHF
9:41am EDT
Change (% chg)

CHF6.10 (+2.28%)
Prev Close
CHF267.00
Open
CHF268.00
Day's High
CHF273.20
Day's Low
CHF267.60
Volume
358,182
Avg. Vol
416,592
52-wk High
CHF278.40
52-wk Low
CHF189.80

Chart for

About

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The Life Science Ingredients division comprises a... (more)

Overall

Beta: 1.17
Market Cap(Mil.): CHF19,883.16
Shares Outstanding(Mil.): 74.47
Dividend: 2.75
Yield (%): 1.03

Financials

  LONN.S Industry Sector
P/E (TTM): 25.85 222.84 32.59
EPS (TTM): 10.33 -- --
ROI: 8.68 -7.75 12.60
ROE: 16.96 -10.55 14.49

UPDATE 1-Lonza confirms targets as gets off to good start

ZURICH, May 4 Swiss drug ingredients maker Lonza confirmed its guidance on Friday and said it had got off to a good start this year.

May 04 2018

Lonza confirms targets as Q1 gets off to good start

ZURICH, May 4 Swiss drug ingredients maker Lonza confirmed its guidance on Friday and said it had got off to a good start this year.

May 04 2018

Samsung BioLogics' shares slide again; unit's valuation jump questioned

SEOUL Shares in South Korea's Samsung BioLogics Co Ltd fell 3.5 percent on Thursday, a day after losing almost $6 billion in market value as the contract biotech drugmaker was hit by a regulatory probe into its accounting rules.

May 03 2018

Samsung BioLogics' shares slide again; unit's valuation jump questioned

SEOUL, May 3 Shares in South Korea's Samsung BioLogics Co Ltd fell 3.5 percent on Thursday, a day after losing almost $6 billion in market value as the contract biotech drugmaker was hit by a regulatory probe into its accounting rules.

May 03 2018

UPDATE 3-Accounting concerns wipe $6 bln off Samsung BioLogics market value

* Financial watchdog gives preliminary notice to co on measures

May 02 2018

Lonza's virus factory shows gene therapy's Texas-sized promise

ZURICH Swiss drugmaker-for-hire Lonza is betting that trillions of customized viruses made at a giant factory in Texas will be the lucrative raw materials of a medical revolution.

Apr 10 2018

FOCUS-Lonza's virus factory shows gene therapy's Texas-sized promise

ZURICH, April 10 Swiss drugmaker-for-hire Lonza is betting that trillions of customized viruses made at a giant factory in Texas will be the lucrative raw materials of a medical revolution.

Apr 10 2018

BRIEF-Lonza To Establish Cell- And Gene-Therapy Centers Of Excellence

* LONZA TO ESTABLISH CELL- AND GENE-THERAPY CENTERS OF EXCELLENCE TO ACCELERATE GROWTH Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 14 2018

Earnings vs. Estimates